Seeking AlphaCodex · 实盘不做把握 9/10
北京时间·🕒 发布 22:29:54时区推断·⟳ 抓取 22:35:47·⚡ 决策 07-28 22:37:14 +1m27s·91.2 天前
Viking Therapeutics将于7月29日盘后发布二季度业绩，当前仅为财报预告
这条信号只是Seeking Alpha对既定财报发布时间和一致预期EPS的日历提醒，没有披露实际业绩、指引或临床新进展。
📄 原文Seeking Alpha↗ 原文
Viking Therapeutics Q2 2026 Earnings Preview
Earnings News Viking Therapeutics Q2 2026 Earnings Preview Jul 28, 2026, 10:29 AM ET Viking Therapeutics, Inc. (VKTX) S…
不做 Viking Therapeutics（VKTX.US）
仅为财报预告和一致预期摘要，未披露实际业绩或超预期增量，方向无法成立，当前不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 medium · price-in 风险 high ↗
关键理由
- 这条信号只是Seeking Alpha对既定财报发布时间和一致预期EPS的日历提醒，没有披露实际业绩、指引或临床新进展。
主要风险
- 若7月29日盘后正式业绩或管线更新超预期，需要由新信号重新研判。
原文全文
展开原文 · 790 字
Earnings News
Viking Therapeutics Q2 2026 Earnings Preview
Jul 28, 2026, 10:29 AM ET
Viking Therapeutics, Inc. (VKTX) Stock
By
:
Preeti Singh
,
SA News Editor
Viking Therapeutics (
VKTX
) is scheduled to announce Q2 earnings results on Wednesday, July 29th, after market close.
The consensus
EPS estimate is -$1.21
.
Over the last 3 months, EPS estimates have seen 3
upward revisions
and 8 downward.
More on Viking Therapeutics
Viking Therapeutics: Still Cheap, But Watch Double Top
Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate
Viking Therapeutics: Drugs Are In The Pipeline, But Profitability Is Still Unproven
Viking outlines 52-week VANQUISH extension and plans oral VK2735 Phase III start in Q4 2026
Viking Therapeutics net loss widens, cash position falls
Viking Therapeutics Q2 2026 Earnings Preview
Jul 28, 2026, 10:29 AM ET
Viking Therapeutics, Inc. (VKTX) Stock
By
:
Preeti Singh
,
SA News Editor
Viking Therapeutics (
VKTX
) is scheduled to announce Q2 earnings results on Wednesday, July 29th, after market close.
The consensus
EPS estimate is -$1.21
.
Over the last 3 months, EPS estimates have seen 3
upward revisions
and 8 downward.
More on Viking Therapeutics
Viking Therapeutics: Still Cheap, But Watch Double Top
Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate
Viking Therapeutics: Drugs Are In The Pipeline, But Profitability Is Still Unproven
Viking outlines 52-week VANQUISH extension and plans oral VK2735 Phase III start in Q4 2026
Viking Therapeutics net loss widens, cash position falls
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。